NorthStar Medical Radioisotopes has established a partnership with Curadh MTR Inc., a global molecularly targeted radiation (MTR)-focused organization, the company announced recently.

According to a release, NorthStar will supply its high purity, n.c.a. Ac-225 to Curadh for use in its pioneering programs for the treatment of common lethal tumors.

“We are very pleased to enter this supply agreement for n.c.a. Ac-225 with Curadh,” NorthStar CEO Frank Scholz said in a statement. “This supply agreement for n.c.a. Ac-225 with Curadh is an important step in helping to provide molecularly targeted radiation therapies for patients with cancer, and we look forward to working with them going forward.”

The financial terms were not disclosed.